Company Name
MEDTECH CATALONIA
Activity
Manufacture and marketing of respiratory protection equipment.
CIF
B-01936053
Sector
MEDICAL DEVICE
Address
17005 - Girona
EPM Joining Date
10/10/2025
Creation Date
16/09/2020
Founders Sílvia Sabrià Mestras Júlia Ferrer Soler
Auditor
GPM AUDITORS ASSOCIATS SL
Investors email contact
jbellvehi@clyype.com
Company profile
The "Project" is MEDTECH CATALONIA, the holding company. The "initial product" is Clyype, a respiratory protection device. The idea is to incorporate other medical devices into the business through subsidiaries. The parent company will not be sold and is the one we plan to list on the BME Growth or BME Scaleup. The objective is to create an industrial group in the medical device sector that strengthens the productive fabric and has a positive impact on our society. The scope of action is global, depending on the product and the market. We can sell business units or subsidiaries, but not the parent company. The addition of new products will be through mechanisms to attract medical device projects, which we will analyze and incorporate through acquisition, merger, non-monetary contribution, joint venture, etc. However, before listing on the BME Growth or BME Scaleup, we will negotiate the acquisition of one or two companies with consolidated revenue and positive EBITDA, and our business plan and valuation will be presented based on the consolidated business.
Business Model
The "Project" is MEDTECH CATALONIA, the holding company. The "initial product" is Clyype, a respiratory protection device. The idea is to incorporate other medical devices into the business through subsidiaries. The parent company will not be sold and is the one we plan to list on the BME Growth or BME Scaleup. The objective is to create an industrial group in the medical device sector that strengthens the productive fabric and has a positive impact on our society. The scope of action is global, depending on the product and the market. We can sell business units or subsidiaries, but not the parent company. The addition of new products will be through mechanisms to attract medical device projects, which we will analyze and incorporate through acquisition, merger, non-monetary contribution, joint venture, etc. However, before listing on the BME Growth or BME Scaleup, we will negotiate the acquisition of one or two companies with consolidated revenue and positive EBITDA, and our business plan and valuation will be presented based on the consolidated business.
Competitive advantage
The project is based on a product, "Clyype," that has enormous potential and lays the backgrounds for its ideal development and scalability. Clyype is a product that has already been developed into several different products, as it was initially designed for the hospital sector, and adaptations for sectors such as the clean room, the industrial sector, and the veterinary sector have already been manufactured and are being marketed. It is the only bidirectional device in the world, with an inlet and outlet filter, and it is the only reprocessable one. We are developing a combined particle and gas filter that will also be unique in its design and use. We are developing a B2B-2C platform so we can go wherever we are needed, that is, wherever there is a respiratory health alarm. The Medical Device Holding Project for industrial projects is innovative, and the desire to not sell it but instead create wealth and have a positive impact on the region is very attractive. Having a structure and management specialized in medical devices creates many synergies and economies of scale with the incorporation of other medical devices into the portfolio. The model allows for the acquisition of healthcare projects and products and their sale, with inorganic growth and extraordinary profits.
Scalability
The Project is primarily focused on gross operating margin, EBITDA, and scalability. Our medical devices must not only be competitive on price, but primarily on quality, innovation, safety, and sustainability. We will only target markets and customers that value these factors and not just price. We must achieve the maximum price based on the product, market, volume, etc. We have significant potential for reducing manufacturing costs with increased volume. The Project allows for and anticipates extraordinary profits from the sale of production units or subsidiaries. The acquisition of other projects, their growth, and their sale contribute to scalability, beyond maintaining the production and marketing of certain products whose production units are not sold. A hub in Singapore is planned to address the Southeast Asian region and perhaps all of Asia, and the possibility of also having a permanent establishment (with the appropriate legal form) in Puerto Rico, USA, is being analyzed, which we believe will also contribute to scalability.
